Table 1.

Head and neck cancer patients (n = 29) demographics data.

Patient #	Age	HPV Status	TNM Staging	Site	DNA (ng/mL)	Sample Type
1	60–65	Positive	T2N2b	Oropharyngeal	41.6	Plasma
2	55–60	Positive	T2N2bM0	Oropharyngeal	22.5	Plasma
3	55–60	Positive	T3N1	Oropharyngeal	10.2	Plasma
4	65–70	Negative	T3N1	Oropharyngeal	15.4	Plasma
5	60–65	Positive	T3N1a	Oropharyngeal	7.8	Plasma
6	45–50	Positive	T3N2b	Oropharyngeal	10.5	Plasma
7	70–75	Negative	T3N2b	Oropharyngeal	21.8	Plasma
8	55–60	Negative	T3N2b	Oropharyngeal	7.2	Plasma
9	60–65	Positive	T3N2c	Oropharyngeal	38.6	Plasma
10	60–65	Positive	T3N2c	Oropharyngeal	10.2	Plasma
11	65–70	Negative	T3N2c	Oral Cavity	4.5	Plasma
12	60–65	Positive	T3N2c	Oropharyngeal	29.2	Plasma
13	55–60	Positive	T4aN2a	Oropharyngeal	28.4	Plasma
14	60–65	Positive	T4aN2b	Hypopharyngeal	36.4	Plasma
15	60–65	Negative	T4aN2b	Oral Cavity	22.9	Plasma
16	55–60	Negative	T4aN2b	Oral Cavity	4.4	Plasma
17	60–65	Negative	T4aN2b	Oral Cavity	29.7	Plasma
18	60–65	Negative	T4aN2c	Laryngeal	10.3	Plasma
19	65–70	Positive	T4N0	Oral Cavity	21.9	Plasma
20	45–50	Negative	T4N0	Unknown	6.0	Plasma
21	65–70	Negative	T4N0	Oral Cavity	27.1	Plasma
22	65–70	Positive	T4N2b	Oropharyngeal	20.1	Plasma
23	45–50	Positive	T4N2b	Oropharyngeal	32.4	Plasma
24	65–70	Negative	T4N2b	Oral Cavity	9.0	Plasma
25	50–55	Negative	T4N2b	Oropharyngeal	7.7	Plasma
26	35–40	Negative	T4N2b	Oral Cavity	12.0	Plasma
27	Unknown	Positive	T4N2c	Unknown	7.3	Plasma
28	65–70	Negative	T4N0	Oral Cavity	9.8	Plasma
29	60–65	Negative	T4N0	Oral Cavity	8.5	Plasma

# Patient number; HPV: Human papillomavirus; TNM: Tumour-node-metastasis staging.